Sympathomimetic and Inotropic Agents

Sympathomimetic and inotropic agents are drug classes that increase the force or rate of cardiac contraction and modulate vascular tone, either by mimicking the sympathetic nervous system at adrenergic receptors or by acting downstream on the contractile machinery of the cardiomyocyte. The group spans the catecholamines, phosphodiesterase inhibitors, cardiac glycosides, and newer calcium sensitizers, and it is central to the pharmacology of acute heart failure and circulatory shock.

Definition

Sympathomimetics are agents that reproduce or enhance the actions of the sympathetic nervous system, typically through adrenergic receptors; positive inotropic (cardiotonic) agents are drugs that increase the contractile force of the myocardium, whether by adrenergic stimulation, inhibition of cyclic-nucleotide breakdown, inhibition of the sodium-potassium ATPase, or sensitization of the contractile proteins to calcium.

Scope

This area orients the reader to agents that raise cardiac contractility (positive inotropy) and to sympathomimetics that act on adrenergic receptors to affect the heart and vasculature. It groups four topics — catecholamine drugs, phosphodiesterase inhibitors, cardiac glycosides, and other inotropic agents (notably calcium sensitizers) — by their distinct mechanisms of action. It is a reference and educational overview of pharmacology, not clinical guidance, and includes no dosing or individualized treatment recommendations.

Sub-topics

• Cardiac Glycosides
• Catecholamine Drugs
• Other Inotropic Agents
• Phosphodiesterase Inhibitors

Core questions

• By what distinct molecular mechanisms do drugs increase myocardial contractility?
• How do adrenergic receptor subtypes (alpha-1, beta-1, beta-2, dopaminergic) map onto the cardiovascular effects of sympathomimetic drugs?
• Why have most positive inotropes failed to improve, and several worsened, long-term survival in heart failure?
• How do the convergent roles of intracellular calcium and cyclic AMP unify these otherwise heterogeneous drug classes?

Key concepts

• Positive inotropy (increased contractile force)
• Adrenergic receptors (alpha-1, beta-1, beta-2) and dopaminergic receptors
• Cyclic AMP and protein kinase A signalling
• Intracellular calcium handling and the sodium-potassium ATPase
• Calcium sensitization of the contractile proteins
• Inotropy versus chronotropy and the myocardial oxygen-demand trade-off
• Sympathomimetic versus direct (post-receptor) inotropic mechanisms

Mechanisms

The agents in this area converge on the intracellular calcium that drives cardiac contraction, but reach it by different routes. Catecholamines and other adrenergic agonists stimulate beta-1 receptors, raising cyclic AMP through Gs-coupled adenylyl cyclase and increasing calcium entry and contractile force; their alpha and beta-2 actions add vascular effects. Phosphodiesterase-3 inhibitors block the breakdown of cyclic AMP, producing inotropy and vasodilation without direct receptor binding. Cardiac glycosides inhibit the sarcolemmal sodium-potassium ATPase, indirectly raising intracellular calcium through the sodium-calcium exchanger. Calcium sensitizers such as levosimendan increase the responsiveness of the contractile proteins to existing calcium. Because increased contractility raises myocardial oxygen demand and, for cyclic-AMP-dependent agents, can promote arrhythmia, the class illustrates a recurring pharmacological trade-off between short-term haemodynamic benefit and longer-term risk.

Clinical relevance

These agents are part of the pharmacological vocabulary of acute heart failure and shock, and understanding their mechanisms underpins the appraisal of cardiovascular trials. A consistent theme in the evidence is that drugs which improve contractility acutely have generally not improved survival when given chronically, which is itself an important conceptual lesson. This entry describes mechanisms and the structure of the evidence; it is not a basis for individual diagnostic or treatment decisions, and contains no dosing information.

Evidence & guidelines

Major randomized trials shape how this drug area is understood: the Digitalis Investigation Group trial of digoxin, PROMISE and OPTIME-CHF for milrinone, SURVIVE for levosimendan versus dobutamine, and the SOAP II comparison of dopamine and norepinephrine in shock. Contemporary heart-failure guidance, such as the 2021 ESC heart-failure guidelines, summarizes the limited and largely supportive role of these agents. Guideline content here is cited for orientation only and is not reproduced as recommendations.

History

The pharmacology of this area began with William Withering's 1785 account of foxglove (digitalis) for dropsy, the first systematic study of a cardiac glycoside. Adrenergic pharmacology was reframed in 1948 when Raymond Ahlquist proposed alpha and beta adrenergic receptors, and the later molecular characterization of those receptors (work associated with Robert Lefkowitz and colleagues) explained the subtype-specific actions of sympathomimetics. Phosphodiesterase inhibitors and calcium sensitizers emerged in the late twentieth century as attempts to achieve inotropy by post-receptor mechanisms, and the subsequent survival trials reshaped the role of the whole class.

Debates

Should positive inotropes be used beyond short-term haemodynamic support?

Acute contractile benefit has repeatedly failed to translate into survival benefit, and some agents increased mortality in chronic use, so the long-term role of inotropy remains contested and is generally confined to bridging or palliative contexts.

Key figures

• William Withering
• Raymond Ahlquist
• Robert Lefkowitz

Seminal works

• de-backer-2010
• mcdonagh-2021
• lymperopoulos-2013

Frequently asked questions

What is the difference between a sympathomimetic and an inotrope?

A sympathomimetic mimics the sympathetic nervous system by acting on adrenergic receptors; an inotrope is any drug that changes contractile force. Many sympathomimetics (such as the catecholamines) are positive inotropes, but inotropes also include agents like cardiac glycosides and calcium sensitizers that work through non-adrenergic mechanisms.

Why do positive inotropic drugs often fail to improve survival?

Most positive inotropes increase contractility by raising intracellular calcium or cyclic AMP, which also raises myocardial oxygen demand and arrhythmia risk; in several large trials these effects offset the haemodynamic benefit, so chronic use generally did not prolong, and sometimes shortened, survival.